迈威生物-U
(688062)
| 流通市值：72.21亿 | | | 总市值：141.34亿 |
| 流通股本：2.04亿 | | | 总股本：4.00亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 67,555,138.51 | 127,835,534.42 | 99,511,384.04 | 89,961,372.07 |
| 营业收入 | 67,555,138.51 | 127,835,534.42 | 99,511,384.04 | 89,961,372.07 |
| 二、营业总成本 | 282,657,001.66 | 1,175,894,797.97 | 775,388,223.53 | 505,087,817.6 |
| 营业成本 | 884,465.4 | 1,369,837.69 | 404,134.32 | 180,469.26 |
| 税金及附加 | 595,140.2 | 3,798,504.41 | 2,013,908.46 | 1,347,569.31 |
| 销售费用 | 44,149,479.15 | 142,910,915.31 | 161,278,252.49 | 87,182,504.61 |
| 管理费用 | 50,980,021.54 | 225,444,764.85 | 144,203,638.77 | 94,392,523.42 |
| 研发费用 | 182,152,879.71 | 835,781,769.78 | 494,110,768.85 | 340,428,779.68 |
| 财务费用 | 3,895,015.66 | -33,410,994.07 | -26,622,479.36 | -18,444,028.68 |
| 其中:利息费用 | 12,275,953.93 | 13,347,433.37 | 8,745,269.24 | 5,689,045.78 |
| 其中:利息收入 | 8,414,945.84 | 46,884,144.64 | 35,463,400.94 | 24,177,367.36 |
| 加:公允价值变动收益 | 83,056.32 | -3,042,618.94 | 363,863.01 | 213,863.01 |
| 加:投资收益 | 249,193.78 | -1,649,359.74 | 1,366,910.34 | 601,228.34 |
| 资产处置收益 | - | -602.12 | 66,407.41 | 68,779.77 |
| 资产减值损失(新) | -2,741,134.85 | -9,488,212.15 | -5,099,511.13 | -3,019,168.14 |
| 信用减值损失(新) | -19,800.2 | -1,652,768.22 | 965,231.48 | 1,123,371.04 |
| 其他收益 | 11,319,889.02 | 11,313,759.15 | 3,101,798.88 | 1,780,979.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -206,210,659.08 | -1,052,579,065.57 | -675,112,139.5 | -414,357,391.95 |
| 加:营业外收入 | - | 60,235.78 | 60,235.78 | 13,275.78 |
| 减:营业外支出 | 6.98 | 2,768,773.92 | 989,196.52 | 1,020,262.88 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -206,210,666.06 | -1,055,287,603.71 | -676,041,100.24 | -415,364,379.05 |
| 减:所得税费用 | - | 3,523,761.88 | 577,921.58 | 577,921.58 |
| 六、净利润 | -206,210,666.06 | -1,058,811,365.59 | -676,619,021.82 | -415,942,300.63 |
| 持续经营净利润 | -206,210,666.06 | -1,058,811,125.08 | -676,618,781.31 | -415,942,060.12 |
| 终止经营净利润 | - | -240.51 | -240.51 | -240.51 |
| 归属于母公司股东的净利润 | -205,658,524.39 | -1,053,432,676.66 | -673,286,515.5 | -413,525,055.42 |
| 少数股东损益 | -552,141.67 | -5,378,688.93 | -3,332,506.32 | -2,417,245.21 |
| (一)基本每股收益 | -0.51 | -2.64 | -1.68 | -1.03 |
| (二)稀释每股收益 | -0.51 | -2.64 | -1.68 | -1.03 |
| 八、其他综合收益 | 123,084.6 | 3,244,278.37 | 4,789,781.45 | 5,581,924.53 |
| 归属于母公司股东的其他综合收益 | 123,084.6 | 3,244,278.37 | 4,789,781.45 | 5,581,924.53 |
| 九、综合收益总额 | -206,087,581.46 | -1,055,567,087.22 | -671,829,240.37 | -410,360,376.1 |
| 归属于母公司股东的综合收益总额 | -205,535,439.79 | -1,050,188,398.29 | -668,496,734.05 | -407,943,130.89 |
| 归属于少数股东的综合收益总额 | -552,141.67 | -5,378,688.93 | -3,332,506.32 | -2,417,245.21 |
| 公告日期 | 2024-04-30 | 2024-04-09 | 2023-10-26 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |